Denmark-basedZealand Pharma AS says its profile among international investors has benefited hugely since its shares were listed on the US Nasdaq last August, giving it exposure to highlight a promising late-stage proprietary pipeline and ongoing collaborations with Sanofi and Boehringer Ingelheim GMBH.
Hitherto largely known for developing the Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), the Danish biotech has under its CEO Britt...








